Which has stronger earnings & valuation, SGMT or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Sagimet Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sagimet Biosciences $2M 116.64 -$51.04M -$1.34 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is SGMT or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% OKYO Pharma N/A N/A N/A

Does the media refer more to SGMT or OKYO?

In the previous week, OKYO Pharma had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for OKYO Pharma and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.72 beat OKYO Pharma's score of 0.26 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive OKYO Pharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ZSQR or OKYO?

OKYO Pharma has a consensus price target of $5.67, indicating a potential upside of 313.63%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts clearly believe OKYO Pharma is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better earnings & valuation, ZSQR or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coeptis Therapeutics $1.36M 171.31 -$11.92M -$2.52 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Does the media refer more to ZSQR or OKYO?

In the previous week, OKYO Pharma had 7 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 9 mentions for OKYO Pharma and 2 mentions for Coeptis Therapeutics. OKYO Pharma's average media sentiment score of 0.26 beat Coeptis Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, OKYO or RNAC?

OKYO Pharma has higher earnings, but lower revenue than Cartesian Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Cartesian Therapeutics $2.80M 85.83 -$130.30M -$5.90 N/A

Is OKYO or RNAC more profitable?

OKYO Pharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Cartesian Therapeutics -8,550.65% N/A -28.25%

Which has better valuation & earnings, OTLK or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Oncobiologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncobiologics $1.35M 151.89 -$62.42M -$1.17 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is OTLK or OKYO more profitable?

Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% OKYO Pharma N/A N/A N/A

Does the media favor OTLK or OKYO?

In the previous week, OKYO Pharma had 5 more articles in the media than Oncobiologics. MarketBeat recorded 9 mentions for OKYO Pharma and 4 mentions for Oncobiologics. OKYO Pharma's average media sentiment score of 0.26 beat Oncobiologics' score of -0.55 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative OKYO Pharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate OKYO or SIGA?

OKYO Pharma currently has a consensus price target of $5.67, suggesting a potential upside of 313.63%. Given OKYO Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe OKYO Pharma is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, OKYO or SIGA?

Siga Technologies has higher revenue and earnings than OKYO Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Siga Technologies $94.57M 2.64 $23.28M $0.27 12.89

OKYO Pharma (OKYO) Competitors

$1.37 -0.06 (-4.20%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$1.43 +0.06 (+4.38%)

As of 07:25 AM Eastern

Compare

OKYO vs. SGMT, ZSQR, RNAC, OTLK, and SIGA

Should you buy OKYO Pharma stock or one of its competitors? MarketBeat compares OKYO Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OKYO Pharma include Sagimet Biosciences (SGMT), Coeptis Therapeutics (ZSQR), Cartesian Therapeutics (RNAC), Oncobiologics (OTLK), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry.

How does OKYO Pharma compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

OKYO Pharma has lower revenue, but higher earnings than Sagimet Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	116.64	-$51.04M	-$1.34	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

OKYO Pharma's return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
OKYO Pharma	N/A	N/A	N/A

In the previous week, OKYO Pharma had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for OKYO Pharma and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.72 beat OKYO Pharma's score of 0.26 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
OKYO Pharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences has a beta of 3.35, suggesting that its share price is 235% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

Sagimet Biosciences currently has a consensus target price of $25.57, indicating a potential upside of 257.14%. OKYO Pharma has a consensus target price of $5.67, indicating a potential upside of 313.63%. Given OKYO Pharma's higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Sagimet Biosciences and OKYO Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Coeptis Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

In the previous week, OKYO Pharma had 7 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 9 mentions for OKYO Pharma and 2 mentions for Coeptis Therapeutics. OKYO Pharma's average media sentiment score of 0.26 beat Coeptis Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OKYO Pharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

OKYO Pharma has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. OKYO Pharma's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
OKYO Pharma	N/A	N/A	N/A

OKYO Pharma has lower revenue, but higher earnings than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	171.31	-$11.92M	-$2.52	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

OKYO Pharma has a consensus price target of $5.67, indicating a potential upside of 313.63%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts clearly believe OKYO Pharma is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

OKYO Pharma beats Coeptis Therapeutics on 11 of the 13 factors compared between the two stocks.

How does OKYO Pharma compare to Cartesian Therapeutics?

OKYO Pharma (NASDAQ:OKYO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

OKYO Pharma has higher earnings, but lower revenue than Cartesian Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Cartesian Therapeutics	$2.80M	85.83	-$130.30M	-$5.90	N/A

OKYO Pharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

OKYO Pharma presently has a consensus price target of $5.67, suggesting a potential upside of 313.63%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 298.53%. Given OKYO Pharma's higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, OKYO Pharma had 9 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 9 mentions for OKYO Pharma and 0 mentions for Cartesian Therapeutics. OKYO Pharma's average media sentiment score of 0.26 beat Cartesian Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Cartesian Therapeutics	Neutral

OKYO Pharma has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Summary

OKYO Pharma beats Cartesian Therapeutics on 7 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
OKYO Pharma	N/A	N/A	N/A

Oncobiologics currently has a consensus price target of $6.50, indicating a potential upside of 371.01%. OKYO Pharma has a consensus price target of $5.67, indicating a potential upside of 313.63%. Given Oncobiologics' higher probable upside, research analysts plainly believe Oncobiologics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, OKYO Pharma had 5 more articles in the media than Oncobiologics. MarketBeat recorded 9 mentions for OKYO Pharma and 4 mentions for Oncobiologics. OKYO Pharma's average media sentiment score of 0.26 beat Oncobiologics' score of -0.55 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
OKYO Pharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

OKYO Pharma has lower revenue, but higher earnings than Oncobiologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	151.89	-$62.42M	-$1.17	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oncobiologics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market.

Summary

OKYO Pharma beats Oncobiologics on 7 of the 11 factors compared between the two stocks.

How does OKYO Pharma compare to Siga Technologies?

OKYO Pharma (NASDAQ:OKYO) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

In the previous week, OKYO Pharma had 9 more articles in the media than Siga Technologies. MarketBeat recorded 9 mentions for OKYO Pharma and 0 mentions for Siga Technologies. OKYO Pharma's average media sentiment score of 0.26 beat Siga Technologies' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Siga Technologies	Neutral

Siga Technologies has higher revenue and earnings than OKYO Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Siga Technologies	$94.57M	2.64	$23.28M	$0.27	12.89

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 2.7% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OKYO Pharma currently has a consensus price target of $5.67, suggesting a potential upside of 313.63%. Given OKYO Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe OKYO Pharma is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Siga Technologies has a net margin of 21.58% compared to OKYO Pharma's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat OKYO Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Siga Technologies	21.58%	10.60%	8.94%

OKYO Pharma has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Summary

Siga Technologies beats OKYO Pharma on 7 of the 13 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKYO vs. The Competition

Export

Metric	OKYO Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$57.99M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	N/A	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.72	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	-8.56	7.92	10.62	6.14
Net Income	-$4.71M	$23.81M	$3.60B	$331.74M
7 Day Performance	-13.29%	-1.09%	-1.26%	-1.82%
1 Month Performance	-13.84%	2.56%	1.07%	-1.45%
1 Year Performance	-51.42%	42.16%	23.63%	16.32%

OKYO Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKYO OKYO Pharma	4.1041 of 5 stars	$1.37 -4.2%	$5.67 +313.6%	-54.2%	$57.99M	N/A	N/A	7	News Coverage Earnings Report High Trading Volume
SGMT Sagimet Biosciences	3.4847 of 5 stars	$7.88 +1.5%	$25.57 +224.7%	-23.9%	$256.05M	$2M	N/A	8
ZSQR Coeptis Therapeutics	0.1 of 5 stars	$4.96 -11.4%	N/A	-57.6%	$255.09M	$1.36M	N/A	2
RNAC Cartesian Therapeutics	2.567 of 5 stars	$8.63 flat	$32.60 +277.8%	-30.9%	$253.55M	$2.80M	N/A	64
OTLK Oncobiologics	3.0223 of 5 stars	$1.69 -2.6%	$6.50 +285.8%	-36.7%	$251.86M	$1.35M	N/A	20	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKYO) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Competitors

OKYO vs. SGMT, ZSQR, RNAC, OTLK, and SIGA

How does OKYO Pharma compare to Sagimet Biosciences?

Summary

How does OKYO Pharma compare to Coeptis Therapeutics?

Summary

How does OKYO Pharma compare to Cartesian Therapeutics?

Summary

How does OKYO Pharma compare to Oncobiologics?

Summary

How does OKYO Pharma compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Competitors

OKYO vs. SGMT, ZSQR, RNAC, OTLK, and SIGA

How does OKYO Pharma compare to Sagimet Biosciences?

Which has stronger earnings & valuation, SGMT or OKYO?

Is SGMT or OKYO more profitable?

Does the media refer more to SGMT or OKYO?

Which has more risk and volatility, SGMT or OKYO?

Do analysts recommend SGMT or OKYO?

Do institutionals and insiders believe in SGMT or OKYO?

Summary

How does OKYO Pharma compare to Coeptis Therapeutics?

Which has more volatility & risk, ZSQR or OKYO?

Does the media refer more to ZSQR or OKYO?

Do insiders & institutionals have more ownership in ZSQR or OKYO?

Is ZSQR or OKYO more profitable?

Which has better earnings & valuation, ZSQR or OKYO?

Do analysts prefer ZSQR or OKYO?

Summary

How does OKYO Pharma compare to Cartesian Therapeutics?

Which has better valuation and earnings, OKYO or RNAC?

Is OKYO or RNAC more profitable?

Do institutionals & insiders hold more shares of OKYO or RNAC?

Do analysts prefer OKYO or RNAC?

Does the media prefer OKYO or RNAC?

Which has more volatility and risk, OKYO or RNAC?

Summary

How does OKYO Pharma compare to Oncobiologics?

Is OTLK or OKYO more profitable?

Do analysts prefer OTLK or OKYO?

Does the media favor OTLK or OKYO?

Which has better valuation & earnings, OTLK or OKYO?

Do institutionals and insiders have more ownership in OTLK or OKYO?

Which has more risk & volatility, OTLK or OKYO?

Summary

How does OKYO Pharma compare to Siga Technologies?

Does the media prefer OKYO or SIGA?

Which has stronger valuation and earnings, OKYO or SIGA?

Do insiders and institutionals hold more shares of OKYO or SIGA?

Do analysts rate OKYO or SIGA?

Is OKYO or SIGA more profitable?

Which has more volatility & risk, OKYO or SIGA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools